Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
1.090
+0.100 (10.10%)
At close: Dec 20, 2024, 4:00 PM
1.050
-0.040 (-3.67%)
After-hours: Dec 20, 2024, 6:13 PM EST
Plus Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Plus Therapeutics stock have an average target of 13.5, with a low estimate of 8.00 and a high estimate of 19. The average target predicts an increase of 1,138.53% from the current stock price of 1.09.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PSTV stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 1 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 1 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $20 → $19 | Strong Buy | Maintains | $20 → $19 | +1,643.12% | Dec 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +633.94% | Nov 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +633.94% | Nov 15, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $21 → $20 | Strong Buy | Maintains | $21 → $20 | +1,734.86% | Sep 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +633.94% | Aug 16, 2024 |
Financial Forecast
Revenue This Year
6.49M
from 4.91M
Increased by 32.12%
Revenue Next Year
4.89M
from 6.49M
Decreased by -24.60%
EPS This Year
-1.83
from -4.24
EPS Next Year
-1.52
from -1.83
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 9.7M | 6.1M | n/a | |||
| Avg | 6.5M | 4.9M | n/a | |||
| Low | 4.3M | 3.5M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 96.9% | -6.3% | - | |||
| Avg | 32.1% | -24.6% | - | |||
| Low | -12.0% | -45.6% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.63 | -1.18 | -1.22 | |||
| Avg | -1.83 | -1.52 | -1.54 | |||
| Low | -2.00 | -1.62 | -2.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.